癌症患者亚段肺栓塞的临床特征与结局
12个月内18例(8.7%)出现复发性PE,抗凝治疗者PE复发率较低(8% vs 13%),抗凝对总生存无显著影响(P = .48)。
要点
- 癌症患者SSPE多为分期CT偶然发现且单发孤立。
- 12个月内复发性PE发生率为8.7%。
- 抗凝治疗者PE复发率低于未抗凝者(8% vs 13%)。
核心结论
- 癌症患者诊断SSPE后12个月内复发性PE发生率为8.7%,抗凝治疗与较低的PE复发率相关。
研究设计与样本
- 回顾性分析206例2014至2016年在德克萨斯大学MD安德森癌症中心诊断为SSPE的成人癌症患者。
主要发现
- 诊断SSPE时多数患者为转移性癌症,108例(53.2%)正在接受化疗,23例(11.2%)有VTE病史。
- 12个月内18例(8.7%)发现复发性PE。
- 抗凝治疗者PE复发率为8%,未抗凝者为13%。
- 调整ECOG体能状态和癌症分期后,抗凝治疗对总生存无显著影响(P = .48)。
临床怎么用
- 癌症患者发现SSPE后应评估复发风险,抗凝治疗可能降低PE复发且未显著影响总生存。
局限性
- 回顾性研究设计,缺乏随机对照临床试验证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the cancer population, patients diagnosed with venous thromboembolism (VTE) are considered to have a threefold increased risk of mortality compared with those without VTE. With the advent of modern computed tomography (CT), the rate of diagnosis of subsegmental pulmonary embolism (SSPE) has increased, likely as a result of improved visualization of the peripheral pulmonary arteries. The clinical significance of SSPE remains unclear because of the lack of randomized controlled clinical trials. The aim of this study was to identify the incidence and risk factors of recurrent proximal PE within 12 months of diagnosis of SSPE in cancer. We performed a retrospective analysis of 206 adult cancer patients who were diagnosed with SSPE from 2014 to 2016 at the University of Texas MD Anderson Cancer Center. At the time of SSPE diagnosis, the majority had metastatic cancer, 108 patients (53.2%) were undergoing chemotherapy, and 23 patients (11.2%) had a history of VTE. Most patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Sixty-seven percent of SSPE was discovered incidentally on restaging CT scans, with the majority being a single and isolated event (70.9%). Within 12 months of SSPE diagnosis, 18 patients (8.7%) were found to have a recurrent PE. The patients treated with anticoagulation had a lower rate of PE recurrence (8% vs 13% in those not treated with anticoagulation). Treatment with anticoagulation did not appear to have a significant impact on overall survival (P = .48) when adjusted for ECOG performance status and cancer stage.
引用
- Yan M, Kieser R, Wu CC, et al. Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients. Blood Adv. 2021. PMID: 33599740. doi:10.1182/bloodadvances.2020003136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。